This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Heart Failure Foundation Course 2025: Chronic heart failure with reduced ejection fraction (HFrEF) – burden, symptoms and diagnosis
ENTRESTO® (sacubitril/valsartan) is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).1
For further information, please refer to the ENTRESTO Summary of Product Characteristics.
Click on the video below to learn more about chronic HFrEF, delving into disease burden, symptoms and diagnosis.
HFrEF, heart failure with reduced ejection fraction.
Reference
ENTRESTO (sacubitril/valsartan) Summary of Product Characteristics.
UK | November 2025 | FA-11549084
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.